Association of syndecan-1 with angiogenesis-related markers, extracellular matrix components, and clinicopathological features in colorectal carcinoma

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 3977-3985

  Mitselou, Antigony ^a   Skoufi, Urania ^a   Tsimogiannis, Konstantinos E ^b   Briasoulis, Evagelos ^b   Vougiouklakis, Theodoros ^a   Arvanitis, Dimitris ^c   Ioachim, Elli ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b General Hospital G Hatzikostas   (Greece)

^c UNIVERSITY OF THESSALY   (Greece)

Author keywords

Angiogenesis; Colorectal cancer; Extracellular matrix; Syndecan 1

Indexed keywords

COLLAGEN TYPE 4; FIBRONECTIN; LAMININ; SYNDECAN 1; TENASCIN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER PROGNOSIS; COLORECTAL CANCER; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; COLLAGEN TYPE IV; COLORECTAL NEOPLASMS; EXTRACELLULAR MATRIX; FEMALE; FIBRONECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; LAMININ; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; SYNDECAN-1; TENASCIN;

EID: 84867015445     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer Statistics, 2009. CA Cancer J Clin 59: 225-259, 2009.
2. Markowitz SD, Dawson DM, Willis J and Wilson JK: Focus on colon cancer. Cancer Cell 1: 233-236, 2002.
3. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL and Atkins D: Gene expression profiles and molecular markers to predict recurrence of Duke's B colon cancer. J Clin Oncol 22: 1564-1571, 2004.
4. Liotta LA and Kohn EC: The microenvironment of the tumour host interface. Nature 411: 375-379, 2001.
5. Friedl P and Wolf K: Tumour cell invasion and migration: diversity and escape mechanisms. Nature Rev Cancer 3: 362-374, 2003.
6. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL and Lose EJ: Biology of the syndecans: a family of transmembrane heparan sulphate proteoglycans. Annu Rev Cell Biol 8: 365-393, 1992.
7. Jalkanen M, Elenius K and Rapraeger A: Syndecan regulator of cell morphology and growth factor action at the cell-matrix interface. Trends Glycosci Glycotechn 5: 107-120, 1993.
8. Woods A: Syndecans: transmembrane modulators of adhesion and matrix assembly. J Clin Inves 107: 935-941, 2001.
9. Hayashi K, Hayashi M, Jalkanen M, Firestone JH, Trelstad RL and Bernfield M: Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron microscopic study. J Histochem Cytochem 35: 1079-1088, 1987.
10. Boutin EL, Sanderson RD, Nernfield M and Cunha GR: Epithelial mesenchymal interactions in uterus and vagina after the expression of cell surface proteoglycan, syndecan. Dev Biol 148: 63-74, 1991.
11. Elenius K, Salmivirta M, Inki P, Mali M and Jalkanen M: Binding of human syndecan to extracellular matrix proteins. J Biol Chem 65: 17837-17843, 1990.
12. Saunders S and Bernfield M: Cell surface proteoglycan binds mouse mammary epithelial cells to fibronectin and behaves as a receptor for interstitial matrix. J Cell Biol 106: 423-430, 1988.
13. Sun X, Mosher DF and Rapraeger A: Heparan sulfate-mediated binding of epithelial cell surface proteoglycan to thrombospondin. J Biol Chem 264: 2885-2889, 1989.
14. Salmivirta M, Elenius K and Vainio S: Syndecan from embryonic tooth mesenchyme binds tenascsin. J Biol Chem 266: 7733-7739, 1991.
15. Elenius K, Maatta A, Salmivirta M and Jalkanen M: Growth factors induce 3T3 cells to express bFGF-binding syndecan. J Biol Chem 267: 6435-6441, 1992.
16. Folkman J and Shing Y: Control of angiogenesis by heparin and other sulphated polyseaccharides. Adv Exp Med Biol 313: 355-364, 1992.
17. Inki P, Stenback F, Talve L and Jalkanen M: Immunohistochemical localization of syndecan in mouse skin tumours induced by UV irradiation. Loss of expression associated with malignant transformation. Am J Pathol 139: 1333-1340, 1991.
18. Wiksten JP, Lundin J and Nordling S: Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer 95: 1-6, 2001.
19. Inki P, Kyjari H and Jalkanen M: Syndecan in carcinomas produced from transformed epithelial cells in nude mice. Lab Invest 66: 314-323, 1992.
20. Leppa S, Hakonen P and Jalkanen M: Steroid-induced epithelial- fibroblastic conversion associated with syndecan suppression in S115 mouse mammary tumor cells. Cell Resul 2: 1-11, 1991.
21. Conejo Jr, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, Bicheng N, Zimmermann A, Kolc M, Friess H and Buchler MW: Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer 88: 12-20, 2000.
22. Matsuda K, Maruyama H and Guo F: Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res 61: 5562-5569, 2001.
23. Inki P, Joensuu H, Grenman R, Klemi P and Jalkanen M: Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br J Cancer 70: 319-323, 1994.
24. Matsumoto A, Ono M, Fujimoto Y, Gallo RL, Bernfield M and Kohgo Y: Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 74: 482-491, 1997.
25. Pulkkinen JO, Penttinen M, Jalkanen M, Klemi P and Grenman R: Syndecan-1: A new prognostic marker in laryngeal cancer. Acta Otoryngol 117: 312-315, 1997.
26. Fujiya M, Watari J, Ashida T, Honda M, Fujiki T, Saitoh Y and Kohgo Y: Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn J Cancer Res 92: 1074-1081, 2001.
27. Zellweyer T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, Mihatsch MJ, Gelmann EP and Bubendorf L: Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostatic cancer. Prostate 55: 20-29, 2003.
28. Anttonen A, Heikkila P, Kojanti M, Jalkenen M and Joenusu H: High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery. Lung Cancer 32: 297-305, 2001.
29. Kumar-Singh S, Jacobs W and Dhaene K: Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol 186: 300-305, 1998.
30. Day RM, Hao X, Ilyas M, Daszak P, Talbot IC and Forbes A: Changes in the expression of syndecan-1 in the colorectal adenoma carcinoma sequence. Virchows Arch 434: 121-125, 1999.
31. Lundin M, Noerdling S, Isola J, Wiksten JP and Haglund C: Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology 68: 306-313, 2005.
32. Mennerich D, Vogel A, Klaman I, Dahl E, Lichtner RB, Rosenthal A, Pohlenz HD, Thierauch KH and Sommer A: Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumors. Eur J Cancer 40: 1373-1382, 2004.
33. Slater M: Dynamic interactions of the extracellular matrix. Histol Histopathol 11: 175-180, 1996.
34. Timple R: Structure and biological activity of basement membrane proteins. Eur J Biochem 180: 487-502, 1989.
35. Compton CC and Greene FL: The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 54: 295-308, 2004.
36. Hamilton SR and Honen A. Pathology and genetics tumors of the digestive system. World Health Organization Classification of Tumours. IARC Press, Lyon, 2000.
37. George B, Kopetz S: Predictive and prognostic markers in colorectal cancer. Curr Oncol Rep 13: 206-215, 2011.
38. Inki P, Stuback F, Gremman S and Jalkanen M: Immunohistochemical localization of syndecan-1 in normal and pathological uterine cervix. J Pathol 172: 349-355, 1991.
39. Ro Y, Muramatsu K, Shima Y, Yajima T, Shibahana H, Noma H and Shimono M: Correlation between reduction of syndecan-1 expression and clinicopathological parameters in squamous cell carcinoma of the tongue. Int J Oral Maxillofac Surg 35: 252-257, 2006.
40. Kivintemi J, Kallajoki M, Kujala T, Matikainen MT, Alanen K, Jalkanen M and Salmivirita M: Altered expression of syndecan-1 in prostate cancer. APMIS 112: 89-97, 2004.
41. Mitselou A, Ioachim E, Peschos D, Charalabopoulos K, Michael M, Agnantis NJ and Vougiouklakis T. E-Cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies. Exp Oncol 29: 54-60, 2007.
42. Gokden N, Greene GF, Bayer-Garner IB, Spencer HJ, Sanderson RD and Godken M: Expression of CD138 (syndecan-1) in renal cell carcinoma is reduced with increasing nuclear grade. App Immunohistochem Mol Morphol 14: 173-177, 2006.
43. Peretti T, Wainsberg J, Nader AM, de Matos LL, da Costa RB, Conccicao GM, Lopes AC, Nader HB and Pinhal MA: Heparanase-2, syndecan-1 and extracellular matrix remodelling in colorectal carcinoma. Eur J Gastroenterol Hepatol 20: 756-765, 2008.
44. Hashimoto Y, Skacel M and Adams JC: Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: An immunohistochemical study of clinically annotated tumors. BMC Cancer 8: 179-185, 2008.
45. Pap Z, Pavai Z, Denes L, Kovalszki I and Jung J. An immunohistochemical study of colon adenomas and carcinomas: E-cadherin, syndecan-1, ETS-1. Pathol Oncol Res 15: 579-587, 2009.
46. Tsanou E, Ioachim E, Briasoulis E, Charchanti A, Damala K, Karavasilis V, Pavlidis N and Agnantis NJ: Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. Correlation with extracellular matrix components. J Exp Clin Cancer 23: 641-650, 2004.
47. Lofgren L, Sahlin L, Jiang S, von Schoultz B, Fernstad R, Skoog L and von Schoultz E: Expression of syndecan-1 in paired samples of normal and malignant breast tissue from postmenopausal women. Anticancer Res 27: 3045-3050, 2007.
48. Juuti A, Nordling S, Jundin J, Louhimo J and Halglund C: Syndecan-1 expression. A novel prognostic marker in pancreatic cancer. Oncology 68: 97-106, 2005.
49. Ito Y, Yoshida H, Nakano K, Takamura Y, Miya A, Koboyashi K, Yokozawa T, Matsuzuka F, Matuura N, Kuma K and Miyauchi A: Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation. Histopathology 43: 157-164, 2004.
50. Bendarda R, Buhmeida A, Hilska M, Laato M, Syrjanen S, Syrjanen K, Collan Y and Pyrhonen S: VEGF1 expression in colorectal cancer is associated with disease localization, stage and long-term disease-specific survival. Anticancer Res 28: 38-65-3870, 2008.
51. Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC and Sanderson RD: Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115: 2449-2457, 2010.
52. Hanamura N, Yoshida T, Matsumoto E, Kawarada Y and Sakakura T: Expression of fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas. Int J Cancer 73: 10-15, 1997.